Literaturverzeichnis

Empfehlungen für die Therapie der Depression. Arzneiverordnung in der Praxis. Arzneimittelkommission der deutschen Ärzteschaft, 1997.

Abelson, J. L., and Curtis, G. C. Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. *Arch Gen Psychiatry* (1996) 53(4):323-31.

Abou-Saleh, M., Merry, J., Coppen, A. Dexamethasone suppression test in alcoholism. *Acta Psychiatr Scand* (1984) 69(2):112-6.

Adli, M., Rush, A. J., Moller, H. J., et al. Algorithms for optimizing the treatment of depression: making the right decision at the right time. *Pharmacopsychiatry* (2003) 36 Suppl 3:S222-9.

Albala, A. A., Greden, J. F., Tarika, J., et al. Changes in serial dexamethasone suppression tests among unipolar depressive receiving electroconvulsive treatment. *Biol Psychiatry* (1981) 16(6):551-60.

Alvarez, E., Perez-Sola, V., Perez-Blanco, J., et al. Predicting outcome of lithium added to antidepressants in resistant depression. *J Affect Disord* (1997) 42(2-3):179-86.

Ames, D., Burrows, G., Davies, B., et al. A study of the dexamethasone suppression test in hospitalized depressed patients. *Br J Psychiatry* (1984) 144:311-3.

Amsterdam, J. D., Winokur, A., Bryant, S., et al. The dexamethasone suppression test as a predictor of antidepressant response. *Psychopharmacology (Berl)* (1983) 80(1):43-5.

Amsterdam, J. D., Maislin, G., Droba, M., et al. The ACTH stimulation test before and after clinical recovery from depression. *Psychiatry Res* (1987a) 20(4):325-36.

Amsterdam, J. D., Marinelli, D. L., Arger, P., et al. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: a pilot study. *Psychiatry Res* (1987b) 21(3):189-97.

Anderson, I. M., and Tomenson, B. M. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. *Bmj* (1995) 310(6992):1433-8.

Anderson, I. M. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. *Depress Anxiety* (1998) 7 Suppl 1:11-7.

Anderson, I. M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. *J Affect Disord* (2000) 58(1):19-36.

Anderson, I. M. Meta-analytical studies on new antidepressants. *Br Med Bull* (2001) 57:161-78.

Anderson, I. M., Tomenson, B.M. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. *J Psychopharmacol* (1994) 8(4):238-249.

Anghelescu, I., Regen, F. Eines oder beide Transmittersysteme angehen? *DNP* (2005) 11:31-36.

APA. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. *Am J Psychiatry* (2000) 157(4 Suppl):1-45.

Arana, G. W., Workman, R. J., and Baldessarini, R. J. Association between low plasma levels of dexamethasone and elevated levels of cortisol in psychiatric patients given dexamethasone. *Am J Psychiatry* (1984) 141(12):1619-20.

Arana, G. W., Baldessarini, R. J., and Ornsteen, M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. *Arch Gen Psychiatry* (1985a) 42(12):1193-204.

Arana, G. W., Wilens, T. E., and Baldessarini, R. J. Plasma corticosterone and cortisol following dexamethasone in psychiatric patients. *Psychoneuroendocrinology* (1985b) 10(1):49-60.

Arato, M., Rihmer, Z., Szadoczky, E., et al. Dexamethasone suppression test as a predictor of drug treatment response. *Prog Neuropsychopharmacol Biol Psychiatry* (1984) 8(4-6):649-52.

Asnis, G. M., Sachar, E. J., Halbreich, U., et al. Cortisol secretion and dexamethasone response in depression. *Am J Psychiatry* (1981a) 138(9):1218-21.

Asnis, G. M., Sachar, E. J., Halbreich, U., et al. Cortisol secretion in relation to age in major depression. *Psychosom Med* (1981b) 43(3):235-42.

Baghai, T. C., Schule, C., Zwanzger, P., et al. Evaluation of a salivary based combined dexamethasone/CRH test in patients with major depression. *Psychoneuroendocrinology* (2002) 27(3):385-99.

Barbui, C., and Hotopf, M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. *Br J Psychiatry* (2001) 178:129-44.

Barden, N., Reul, J. M., and Holsboer, F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? *Trends Neurosci* (1995) 18(1):6-11.

Baron, J. A., Comi, R. J., Cryns, V., et al. The effect of cigarette smoking on adrenal cortical hormones. *J Pharmacol Exp Ther* (1995) 272(1):151-5.

Bauer, M., and Dopfmer, S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. *J Clin Psychopharmacol* (1999) 19(5):427-34.

Bauer, M., Whybrow, P. C., Angst, J., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. *World J Biol Psychiatry* (2002a) 3(1):5-43.

Bauer, M., Whybrow, P. C., Angst, J., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. *World J Biol Psychiatry* (2002b) 3(2):69-86.

Bauer, M., Forsthoff, A., Baethge, C., et al. Lithium augmentation therapy in refractory depression-update 2002. *Eur Arch Psychiatry Clin Neurosci* (2003) 253(3):132-9.

Bauer, M., Stamm, T., Sasse, J., et al. Duloxetin - ein neues Antidepressivum mit dualem Wirkmechanismus. *Die Psychiatrie* (2005) 2:244-51.

Baumgartner, A., Haack, D., and Vecsei, P. Serial dexamethasone suppression tests in psychiatric illness: Part III. The influence of intervening variables. *Psychiatry Res* (1986a) 18(1):45-64.

Baumgartner, A., Graf, K. J., and Kurten, I. Serial dexamethasone suppression tests in psychiatric illness: Part II. A study in major depressive disorder. *Psychiatry Res* (1986b) 18(1):25-43.

Baumgartner, A., Graf, K. J., and Kurten, I. Serial dexamethasone suppression tests in psychiatric illness: Part I. A study in schizophrenia and mania. *Psychiatry Res* (1986c) 18(1):9-23.

Beary, M. D., Lacey, J. H., and Bhat, A. V. The neuro-endocrine impact of 3-hydroxy-diazepam (temazepam) in women. *Psychopharmacology (Berl)* (1983) 79(4):295-7.

Bech, P., Cialdella, P., Haugh, M. C., et al. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. *Br J Psychiatry* (2000) 176:421-8.

Beckmann, H., Holzmuller, B., and Fleckenstein, P. Clinical investigations into antidepressive mechanisms. II. Dexamethasone suppression test predicts response to nomifensine or amitriptyline. *Acta Psychiatr Scand* (1984) 70(4):342-53.

Benkelfat, C., Poirier, M. F., Leouffre, P., et al. Dexamethasone suppression test and the response to antidepressant depending on their central monoaminergic action in major depression. *Can J Psychiatry* (1987) 32(3):175-8.

Benkert, O., Grunder, G., Wetzel, H., et al. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. *J Psychiatr Res* (1996) 30(6):441-51.

Benkert, O., Gründer, G., Wetzel, H. Bietet Venlafaxin einen Vorteil gegenüber anderen Antidepressiva? *Human Psychopharmacology* (1997) 12:53-64.

Benkert, O., Hippius, H. *Psychiatrische Pharmakotherapie*. Springer-Verlag, 1996.

Benkert, O., Hippius, H. *Kompendium der Psychiatrischen Pharmakotherapie*. Springer Medizin Verlag, 2005.

Berger, M., Doerr, P., Lund, R., et al. Neuroendocrinological and neurophysiological studies in major depressive disorders: are there biological markers for the endogenous subtype? *Biol Psychiatry* (1982) 17(11):1217-42.

Berger, M., Pirke, K. M., Doerr, P., et al. Influence of weight loss on the dexamethasone suppression test. *Arch Gen Psychiatry* (1983) 40(5):585-6.

Berger, M., and Klein, H. E. [Dexamethasone suppression test: a biologic marker of endogenous depression?]. *Eur Arch Psychiatry Neurol Sci* (1984) 234(2):137-46.

Berger, M., Pirke, K. M., Doerr, P., et al. The limited utility of the dexamethasone suppression test for the diagnostic process in psychiatry. *Br J Psychiatry* (1984) 145:372-82.

Berger, M., Krieg, C., Bossert, S., et al. Past and present strategies of research on the HPA-axis in psychiatry. *Acta Psychiatr Scand Suppl* (1988) 341:112-25.

Berger, M. Pharmakologische Akut- und Langzeittherapie unipolarer Depressionen. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2004a) 75(Suppl 2):127.

Berger, M., van Calker, D. Affektive Störungen. In M. Berger, ed., *Psychische Erkrankungen*. Urban & Fischer Verlag, 2004b.

Black, D. W., Monahan, P. O., and Winokur, G. The relationship between DST results and suicidal behavior. *Ann Clin Psychiatry* (2002) 14(2):83-8.

Bleuler, M. The Internal Secretions and the Nervous System. *The Journal of Nervous and Mental Disease* (1919) Monograph Series No. 30.

Bleuler, M. Untersuchungen aus dem Grenzgebiet zwischen Psychopathologie und Endokrinologie. *Arch Psychiat Nervenkr.* (1948) 180:271-528.

Board, F., Persky, H., and Hamburg, D. A. Psychological stress and endocrine functions; blood levels of adrenocortical and thyroid hormones in acutely disturbed patients. *Psychosom Med* (1956) 18(4):324-33.

Board, F., Wadeson, R., and Persky, H. Depressive affect and endocrine functions; blood levels of adrenal cortex and thyroid hormones in patients suffering from depressive reactions. *AMA Arch Neurol Psychiatry* (1957) 78(6):612-20.

Bowie, P. C., and Beaini, A. Y. Normalisation of the dexamethasone suppression test: a correlate of clinical improvement in primary depressives. *Br J Psychiatry* (1985) 147:30-5.

Brady, L. S., Gold, P. W., Herkenham, M., et al. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. *Brain Res* (1992) 572(1-2):117-25.

Brizer, D. A., Brown, R. P., Kocsis, J. H., et al. Interepisode consistency of dexamethasone suppression test results in affective disorders. *Am J Psychiatry* (1986) 143(4):539-41.

Brown, G. M. Psychoneuroendocrinology of depression. *Psychiatr J Univ Ott* (1989) 14(2):344-8; discussion 349-51.

Brown, W. A., Johnston, R., and Mayfield, D. The 24-hour dexamethasone suppression test in a clinical setting: relationship to diagnosis, symptoms, and response to treatment. *Am J Psychiatry* (1979) 136(4B):543-7.

Brown, W. A., and Shuey, I. Response to dexamethasone and subtype of depression. *Arch Gen Psychiatry* (1980) 37(7):747-51.

Brown, W. A., Haier, R. J., and Qualls, C. B. Dexamethasone suppression test identifies subtypes of depression which respond to different antidepressants. *Lancet* (1980) 1(8174):928-9.

Brown, W. A., and Qualls, C. B. Pituitary-adrenal disinhibition in depression: marker of a subtype with characteristic clinical features and response to treatment? *Psychiatry Res* (1981) 4(2):115-28.

Brown, W. A., and Qualls, C. B. Pituitary-adrenal regulation over multiple depressive episodes. *Psychiatry Res* (1982) 7(3):265-9.

Brown, W. A., Haltzman, S. D., Fruzzetti, A., et al. Consistency of pituitary-adrenocortical function across multiple psychiatric hospitalizations. *Psychiatry Res* (1986) 18(3):203-8.

Brown, W. A., Shrivastava, R. K., and Arato, M. Pre-treatment pituitary-adrenocortical status and placebo response in depression. *Psychopharmacol Bull* (1987) 23(1):155-9.

Bschor, T., Adli, M., Baethge, C., et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. *Neuropsychopharmacology* (2002) 27(3):470-8.

Bschor, T., Baethge, C., Adli, M., et al. Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. *J Psychiatr Res* (2003a) 37(2):135-43.

Bschor, T., Baethge, C., Adli, M., et al. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. *Depress Anxiety* (2003b) 17(1):43-8.

Bunney, W. E., Jr., and Davis, J. M. Norepinephrine in depressive reactions. A review. *Arch Gen Psychiatry* (1965) 13(6):483-94.

Burke, H. M., Davis, M. C., Otte, C., et al. Depression and cortisol responses to psychological stress: a meta-analysis. *Psychoneuroendocrinology* (2005) 30(9):846-56.

Carroll, B. J., Feinberg, M., Greden, J. F., et al. Diagnosis of endogenous depression. Comparison of clinical, research and neuroendocrine criteria. *J Affect Disord* (1980) 2(3):177-94.

Carroll, B. J., Feinberg, M., Greden, J. F., et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. *Arch Gen Psychiatry* (1981) 38(1):15-22.

Carroll, B. J. Dexamethasone suppression test for depression. *Adv Biochem Psychopharmacol* (1984) 39:179-88.

Carson, S. W., Halbreich, U., Yeh, C. M., et al. Liver function, plasma dexamethasone, and DST results in detoxified alcoholics. *Psychiatry Res* (1989) 30(2):217-21.

Cassidy, F., Ritchie, J. C., and Carroll, B. J. Plasma dexamethasone concentration and cortisol response during manic episodes. *Biol Psychiatry* (1998) 43(10):747-54.

Catalan, R., Gallart, J. M., Castellanos, J. M., et al. Plasma corticotropin-releasing factor in depressive disorders. *Biol Psychiatry* (1998) 44(1):15-20.

Charles, G. A., Schittecatte, M., Rush, A. J., et al. Persistent cortisol non-suppression after clinical recovery predicts symptomatic relapse in unipolar depression. *J Affect Disord* (1989) 17(3):271-8.

Clerc, G. E., Ruimy, P., and Verdeau-Palles, J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. *Int Clin Psychopharmacol* (1994) 9(3):139-43.

Clower, C. G. DST has no predictive ability for acute response to ECT. *J Clin Psychiatry* (1986) 47(12):612.

Coffey, C. E., Wilkinson, W. E., Weiner, R. D., et al. The dexamethasone suppression test and quantitative cerebral anatomy in depression. *Biol Psychiatry* (1993) 33(6):442-9.

Coppen, A., Abou-Saleh, M., Milln, P., et al. Dexamethasone suppression test in depression and other psychiatric illness. *Br J Psychiatry* (1983) 142:498-504.

Coppen, A., Harwood, J., and Wood, K. Depression, weight loss and the dexamethasone suppression test. *Br J Psychiatry* (1984) 145:88-90.

Coryell, W. Hypothalamic-pituitary-adrenal axis abnormality and ECT response. *Psychiatry Res* (1982) 6(3):283-91.

Coryell, W., and Schlesser, M. A. Dexamethasone suppression test response in major depression: stability across hospitalizations. *Psychiatry Res* (1983) 8(3):179-89.

Coryell, W., and Zimmerman, M. The dexamethasone suppression test and ECT outcome: a six-month follow-up. *Biol Psychiatry* (1983) 18(1):21-7.

Coryell, W. The use of laboratory tests in psychiatric diagnosis: the DST as an example. *Psychiatr Dev* (1984) 2(3):139-59.

Coryell, W. Are serial dexamethasone suppression tests useful in electroconvulsive therapy? *J Affect Disord* (1986) 10(1):59-66.

Coryell, W. DST abnormality as a predictor of course in major depression. *J Affect Disord* (1990) 19(3):163-9.

Coryell, W., and Schlesser, M. The dexamethasone suppression test and suicide prediction. *Am J Psychiatry* (2001) 158(5):748-53.

Curtis, G. C., Cameron, O. G., and Nesse, R. M. The dexamethasone suppression test in panic disorder and agoraphobia. *Am J Psychiatry* (1982) 139(8):1043-6.

Dackis, C. A., Bailey, J., Pottash, A. L., et al. Specificity of the DST and the TRH test for major depression in alcoholics. *Am J Psychiatry* (1984) 141(5):680-3.

De Kloet, E. R., Vreugdenhil, E., Oitzl, M. S., et al. Brain corticosteroid receptor balance in health and disease. *Endocr Rev* (1998) 19(3):269-301.

De la Fuente, J. M., Bobes, J., Vizuete, C., et al. Effects of carbamazepine on dexamethasone suppression and sleep electroencephalography in borderline personality disorder. *Neuropsychobiology* (2002) 45(3):113-9.

Del Porto, J. A., Monteiro, M. G., Laranjeira, R. R., et al. Reversal of abnormal dexamethasone suppression test in alcoholics abstinent for four weeks. *Biol Psychiatry* (1985) 20(11):1156-60.

Deshauer, D., Grof, E., Alda, M., et al. Patterns of DST positivity in remitted affective disorders. *Biol Psychiatry* (1999) 45(8):1023-9.

Deshauer, D., Duffy, A., Alda, M., et al. The cortisol awakening response in bipolar illness: a pilot study. *Can J Psychiatry* (2003) 48(7):462-6.

Dettling, M. Die klinische Relevanz von State-, Trait- und Residualmarkern für die biologische Psychiatrie am Beispiel neuroendokriner und pharmakogenetischer Befunde, 2000.

Deuschle, M., Schweiger, U., Standhardt, H., et al. Corticosteroid-binding globulin is not decreased in depressed patients. *Psychoneuroendocrinology* (1996) 21(8):645-9.

Deuschle, M., Schmider, J., Weber, B., et al. Pulse-dosing and conventional application of doxepin: effects on psychopathology and hypothalamus-pituitary-adrenal (HPA) system. *J Clin Psychopharmacol* (1997a) 17(3):156-60.

Deuschle, M., Schweiger, U., Weber, B., et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. *J Clin Endocrinol Metab* (1997b) 82(1):234-8.

Deuschle, M., Gotthardt, U., Schweiger, U., et al. With aging in humans the activity of the hypothalamus-pituitary-adrenal system increases and its diurnal amplitude flattens. *Life Sci* (1997c) 61(22):2239-46.

Deuschle, M., Schweiger, U., Gotthardt, U., et al. The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary-adrenocortical system than the dexamethasone suppression test. *Biol Psychiatry* (1998a) 43(10):762-6.

Deuschle, M., Weber, B., Colla, M., et al. Effects of major depression, aging and gender upon calculated diurnal free plasma cortisol concentrations: a re-evaluation study. *Stress* (1998b) 2(4):281-7.

Deuschle, M., Weber, B., Colla, M., et al. Mineralocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans. *Neuroendocrinology* (1998c) 68(5):355-60.

Deuschle, M., and Lederbogen, F. [Depression and cardiovascular disease: pathogenetic factors of the stress concept]. *Fortschr Neurol Psychiatr* (2002) 70(5):268-75.

Deuschle, M., Hamann, B., Meichel, C., et al. Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. *J Clin Psychopharmacol* (2003) 23(2):201-5.

Deuschle, M. Aktivität des HHN-Systems im Verlauf der antidepressiven Therapie. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2006) 77(Suppl 3):355.

Devanand, D. P., Pandurangi, A. K., and Dewan, M. J. False-positive dexamethasone suppression test results related to antipsychotic drug withdrawal: case report. *J Clin Psychiatry* (1984) 45(6):275-6.

Devanand, D. P., Decina, P., Sackeim, H. A., et al. Serial dexamethasone suppression tests in initial suppressors and nonsuppressors treated with electroconvulsive therapy. *Biol Psychiatry* (1987) 22(4):463-72.

Devanand, D. P., Sackeim, H. A., Lo, E. S., et al. Serial dexamethasone suppression tests and plasma dexamethasone levels. Effects of clinical response to electroconvulsive therapy in major depression. *Arch Gen Psychiatry* (1991) 48(6):525-33.

DGPPN. *Praxisleitlinien in Psychiatrie und Psychotherapie, Band 5: Behandlungsleitlinie Affektive Erkrankungen*. Steinkopff Verlag, 2000.

Dilling, H., Mombour, W., and Schmidt, M. H. H. *Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F); WHO*. Verlag Hans Huber, 2000.

Dored, G., Stefansson, S., d'Elia, G., et al. Corticotropin, cortisol and beta-endorphin responses to the human corticotropin-releasing hormone during melancholia and after unilateral electroconvulsive therapy. *Acta Psychiatr Scand* (1990) 82(3):204-9.

Dratcu, L., and Calil, H. M. The dexamethasone suppression test: its relationship to diagnoses, severity of depression and response to treatment. *Prog Neuropsychopharmacol Biol Psychiatry* (1989) 13(1-2):99-117.

DUAG. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. *Psychopharmacology (Berl)* (1986) 90(1):131-8.

DUAG. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. *J Affect Disord* (1990) 18(4):289-99.

Duman, R. S., Heninger, G. R., and Nestler, E. J. A molecular and cellular theory of depression. *Arch Gen Psychiatry* (1997) 54(7):597-606.

Duval, F., Mokrani, M. C., Crocq, M. A., et al. Dopaminergic function and the cortisol response to dexamethasone in psychotic depression. *Prog Neuropsychopharmacol Biol Psychiatry* (2000) 24(2):207-25.

Eichmann, U. Co-A-LA-Studie: Cortisol-Achse vor und während Lithiumaugmentation. *Dissertation FU Berlin* (2004).

Einarson, T. R., Arikian, S. R., Casciano, J., et al. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. *Clin Ther* (1999) 21(2):296-308.

Ettigi, P. G., Hayes, P. E., Narasimhachari, N., et al. d-Amphetamine response and dexamethasone suppression test as predictors of treatment outcome in unipolar depression. *Biol Psychiatry* (1983) 18(4):499-504.

Extein, I., Kirstein, L. S., Pottash, A. L., et al. The dexamethasone suppression and thyrotropin-releasing hormone tests and response to treatment in unipolar depression. *Int J Psychiatry Med* (1982) 12(4):267-74.

Fang, V. S., Tricou, B. J., Robertson, A., et al. Plasma ACTH and cortisol levels in depressed patients: relation to dexamethasone suppression test. *Life Sci* (1981) 29(9):931-8.

Fava, G. A. Subclinical symptoms in mood disorders: pathophysiological and therapeutic implications. *Psychol Med* (1999) 29(1):47-61.

Fichtl, B., Fülgraff, G., Neumann, H.G. Allgemeine Pharmakologie und Toxikologie. In W. Forth, Henschler, D., ed., *Pharmakologie und Toxikologie*. Spektrum Akademischer Verlag, 1998.

Fink, M., Gujavarty, K., and Greenberg, L. Serial Dexamethasone Suppression Tests and Clinical Outcome in ECT. *Convuls Ther* (1987) 3(2):111-120.

Fink, M., and Taylor, M. A. Resurrecting melancholia. *Acta Psychiatr Scand* (2007) 115(Suppl. 433):1-7.

Fiori, M., and Davis, K. L. Possible clinical applications of laboratory tests in depression. *J Clin Psychiatry* (1984) 45(4 Pt 2):6-11.

Folkerts, H. *Elektrokrampftherapie: ein praktischer Leitfaden für die Klinik*. Ferdinand Enke Verlag, 1997.

Fraser, A. R. Choice of antidepressant based on the dexamethasone suppression test. *Am J Psychiatry* (1983) 140(6):786-7.

Frieboes, R. M., Sonntag, A., Yassouridis, A., et al. Clinical outcome after trimipramine in patients with delusional depression - a pilot study. *Pharmacopsychiatry* (2003) 36(1):12-7.

Galard, R., Gallart, J. M., Catalan, R., et al. Salivary cortisol levels and their correlation with plasma ACTH levels in depressed patients before and after the DST. *Am J Psychiatry* (1991) 148(4):505-8.

Galard, R., Catalan, R., Castellanos, J. M., et al. Plasma corticotropin-releasing factor in depressed patients before and after the dexamethasone suppression test. *Biol Psychiatry* (2002) 51(6):463-8.

Garyfallos, G., Lavrentiadis, G., Amoutzias, D., et al. Negative symptoms of schizophrenia and the dexamethasone suppression test. *Acta Psychiatr Scand* (1993) 88(6):425-8.

Gass, P. Glukokortikoid-Rezeptor-Transgene Mäuse als Modell für affektive Störungen. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2004) 75(Suppl 2):104.

Geddes, J. R., Freemantle, N., Mason, J., et al. SSRIs versus other antidepressants for depressive disorder. *Cochrane Database Syst Rev* (2000) (2):CD001851.

Georgotas, A., Stokes, P., McCue, R. E., et al. The usefulness of DST in predicting response to antidepressants: a placebo-controlled study. *J Affect Disord* (1986a) 11(1):21-8.

Georgotas, A., Stokes, P. E., Hapworth, W. E., et al. The relationship of the dexamethasone suppression test to subtypes of depression and to symptomatic severity in the elderly. *J Affect Disord* (1986b) 10(1):51-7.

Georgotas, A., McCue, R. E., Kim, O. M., et al. Dexamethasone suppression in dementia, depression, and normal aging. *Am J Psychiatry* (1986c) 143(4):452-6.

Gibbons, J. L., and Mc, H. P. Plasma cortisol in depressive illness. *J Psychiatr Res* (1962) 1:162-71.

Gibbons, J. L. Cortisol Secretion Rate in Depressive Illness. *Arch Gen Psychiatry* (1964) 10:572-5.

Gibbons, R. D., Hedeker, D., and Davis, J. M. Regression toward the mean: more on the price of beer and the salaries of priests. *Psychoneuroendocrinology* (1987) 12(3):185-92.

Gitlin, M. J., Gwirtsman, H., Fairbanks, L., et al. Dexamethasone suppression test and treatment response. *J Clin Psychiatry* (1984) 45(9):387-9.

Gitlin, M. J., and Gerner, R. H. The dexamethasone suppression test and response to somatic treatment: a review. *J Clin Psychiatry* (1986) 47(1):16-21.

Glassman, A. H., Arana, G. W., Baldessarini, R. J., et al. The dexamethasone suppression test: an overview of its current status in psychiatry. The APA Task Force on Laboratory Tests in Psychiatry. *Am J Psychiatry* (1987) 144(10):1253-62.

Godwin, C. D., Greenberg, L. B., and Shukla, S. Consistent dexamethasone suppression test results with mania and depression in bipolar illness. *Am J Psychiatry* (1984) 141(10):1263-5.

Goggans, F. C., Wilson, W. R., Jr., Gold, M. S., et al. Effect of multiple time point sampling on the sensitivity of the dexamethasone suppression test. *Am J Psychiatry* (1983) 140(7):909-10.

Goldberg, I. K. Dexamethasone suppression test as indicator of safe withdrawal of antidepressant therapy. *Lancet* (1980a) 1(8164):376.

Goldberg, I. K. Dexamethasone suppression tests in depression and response to treatment. *Lancet* (1980b) 2(8185):92.

Grasser, A., Moller, A., Backmund, H., et al. Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis. *Exp Clin Endocrinol Diabetes* (1996) 104(1):31-7.

Greden, J. F., Albala, A. A., Haskett, R. F., et al. Normalization of dexamethasone suppression test: a laboratory index of recovery from endogenous depression. *Biol Psychiatry* (1980) 15(3):449-58.

Greden, J. F., Kronfol, Z., Gardner, R., et al. Dexamethasone suppression test and selection of antidepressant medications. *J Affect Disord* (1981) 3(4):389-96.

Greden, J. F. Biological markers of melancholia and reclassification of depressive disorders. *Encephale* (1982) 8(2):193-202.

Greden, J. F., Gardner, R., King, D., et al. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. *Arch Gen Psychiatry* (1983) 40(5):493-500.

Green, H. S., and Kane, J. M. The dexamethasone suppression test in depression. *Clin Neuropharmacol* (1983) 6(1):7-24.

Greenberg, R. P., Bornstein, R. F., Greenberg, M. D., et al. A meta-analysis of antidepressant outcome under "blinder" conditions. *J Consult Clin Psychol* (1992) 60(5):664-9; discussion 670-7.

Grunhaus, L., Greden, J. F., Carroll, B. J., et al. The dexamethasone suppression test in repeated hospitalizations. *Biol Psychiatry* (1983) 18(12):1497-502.

Grunhaus, L., Zelnik, T., Albala, A. A., et al. Serial dexamethasone suppression tests in depressed patients treated only with electroconvulsive therapy. *J Affect Disord* (1987a) 13(3):233-40.

Grunhaus, L., Flegel, P., Haskett, R. F., et al. Serial dexamethasone suppression tests in simultaneous panic and depressive disorders. *Biol Psychiatry* (1987b) 22(3):332-8.

Guthrie, S. The impact of dexamethasone pharmacokinetics on the DST: a review. *Psychopharmacol Bull* (1991) 27(4):565-76.

Guthrie, S. K., Heidt, M., Pande, A., et al. A longitudinal evaluation of dexamethasone pharmacokinetics in depressed patients and normal controls. *J Clin Psychopharmacol* (1992) 12(3):191-6.

Halbreich, U., Asnis, G. M., Shindledecker, R., et al. Cortisol secretion in endogenous depression. I. Basal plasma levels. *Arch Gen Psychiatry* (1985a) 42(9):904-8.

Halbreich, U., Asnis, G. M., Shindledecker, R., et al. Cortisol secretion in endogenous depression. II. Time-related functions. *Arch Gen Psychiatry* (1985b) 42(9):909-14.

Hamilton, M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* (1960) 23:56-62.

Hatzinger, M., Z'Brun, A., Hemmeter, U., et al. Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. *Neurobiol Aging* (1995) 16(2):205-9.

Hatzinger, M. Neuropeptides and the hypothalamic-pituitary-adrenocortical (HPA) system: review of recent research strategies in depression. *World J Biol Psychiatry* (2000) 1(2):105-11.

Hatzinger, M., Hemmeter, U. M., Baumann, K., et al. The combined DEX-CRH test in treatment course and long-term outcome of major depression. *J Psychiatr Res* (2002) 36(5):287-97.

Heim, C., Ehlert, U. Pharmakologische Provokationstests zur Einschätzung der endokrinen Funktion. In C. Kirschbaum, Hellhammer, D., ed., *Enzyklopädie der Psychologie, Psychoendokrinologie und Psychoimmunologie*. Hogrefe, 1999.

Hellebuyck, H., Maes, M., and Suy, E. Repeated dexamethasone suppression test in major depression. *Acta Psychiatr Belg* (1988) 88(5-6):378-86.

Heuser, I., von Bardeleben, U., Boll, E., et al. Response of ACTH and cortisol to human corticotropin-releasing hormone after short-term abstention from alcohol abuse. *Biol Psychiatry* (1988) 24(3):316-21.

Heuser, I., Yassouridis, A., and Holsboer, F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. *J Psychiatr Res* (1994a) 28(4):341-56.

Heuser, I. Anna-Monika-Prize paper. The hypothalamic-pituitary-adrenal system in depression. *Pharmacopsychiatry* (1998) 31(1):10-3.

Heuser, I., Bissette, G., Dettling, M., et al. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. *Depress Anxiety* (1998) 8(2):71-9.

Heuser, I. Psychoneuroendokrinologie. In H. Helmchen, ed., *Psychiatrie der Gegenwart. Bd. 1*. Springer Verlag, 1999.

Heuser, I., Deuschle, M., Weber, B., et al. Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. *Psychoneuroendocrinology* (2000a) 25(5):513-8.

Heuser, I., Deuschle, M., Weber, A., et al. The role of mineralocorticoid receptors in the circadian activity of the human hypothalamus-pituitary-adrenal system: effect of age. *Neurobiol Aging* (2000b) 21(4):585-9.

Heuser, I. Wenn Kummer das Herz bricht. *DNP* (2003) 4:36-37.

Heuser, I. J., Wark, H. J., Keul, J., et al. Hypothalamic-pituitary-adrenal axis function in elderly endurance athletes. *J Clin Endocrinol Metab* (1991) 73(3):485-8.

Heuser, I. J., Gotthardt, U., Schweiger, U., et al. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. *Neurobiol Aging* (1994b) 15(2):227-31.

Heuser, I. J., Schweiger, U., Gotthardt, U., et al. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. *Am J Psychiatry* (1996) 153(1):93-9.

Hilgers, R.-D., Bauer, P., Scheiber, V. *Einführung in die Medizinische Statistik*. Springer Verlag, 2003.

Hirschfeld, R. M., Montgomery, S. A., Aguglia, E., et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. *J Clin Psychiatry* (2002) 63(9):826-37.

Holsboer, F., Bender, W., Benkert, O., et al. Diagnostic value of dexamethasone suppression test in depression. *Lancet* (1980) 2(8196):706.

Holsboer, F., Haack, D., Gerken, A., et al. Plasma dexamethasone concentrations and differential suppression response of cortisol and corticosterone in depressives and controls. *Biol Psychiatry* (1984a) 19(3):281-91.

Holsboer, F., Von Bardeleben, U., Gerken, A., et al. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. *N Engl J Med* (1984b) 311(17):1127.

Holsboer, F., Philipp, M., and Gerken, A. Dexamethasone suppression test and weight loss. *Psychiatry Res* (1984c) 13(4):353-4.

Holsboer, F., Philipp, M., Steiger, A., et al. Multisteroid analysis after DST in depressed patients--a controlled study. *J Affect Disord* (1986a) 10(3):241-9.

Holsboer, F., Wiedemann, K., Gerken, A., et al. The plasma dexamethasone variable in depression: test-retest studies and early biophase kinetics. *Psychiatry Res* (1986b) 17(2):97-103.

Holsboer, F., Wiedemann, K., and Boll, E. Shortened dexamethasone half-life in depressed dexamethasone nonsuppressors. *Arch Gen Psychiatry* (1986c) 43(8):813-5.

Holsboer, F., von Bardeleben, U., Buller, R., et al. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. *Horm Metab Res Suppl* (1987a) 16:80-8.

Holsboer, F., Gerken, A., Stalla, G. K., et al. Blunted aldosterone and ACTH release after human CRH administration in depressed patients. *Am J Psychiatry* (1987b) 144(2):229-31.

Holsboer, F., von Bardeleben, U., Wiedemann, K., et al. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. *Biol Psychiatry* (1987c) 22(2):228-34.

Holsboer, F. Dynamische Systemerkrankungen: Depression. In R. Hesch, ed., *Innere Medizin der Gegenwart: Endokrinologie, Bd. 5, Teil B*. Urban & Schwarzenberg, 1989.

Holsboer, F., Spengler, D., and Heuser, I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. *Prog Brain Res* (1992) 93:385-417.

Holsboer, F., Lauer, C. J., Schreiber, W., et al. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. *Neuroendocrinology* (1995) 62(4):340-7.

Holsboer, F., and Barden, N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. *Endocr Rev* (1996) 17(2):187-205.

Holsboer, F. The stress hormone system is back on the map. *Curr Psychiatry Rep* (2000a) 2(6):454-6.

Holsboer, F. The corticosteroid receptor hypothesis of depression. *Neuropsychopharmacology* (2000b) 23(5):477-501.

Holsboer, F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. *J Affect Disord* (2001) 62(1-2):77-91.

Holsboer, F. Corticotropin-releasing hormone modulators and depression. *Curr Opin Investig Drugs* (2003) 4(1):46-50.

Holsboer, F., Liebl, R., Hofschuster, E. Repeated Dexamethasone Suppression Test during Depressive Illness. *J Affect Disord* (1982) 4:93-101.

Holsboer-Trachsler, E., Stohler, R., and Hatzinger, M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. *Psychiatry Res* (1991) 38(2):163-71.

Holsboer-Trachsler, E. Therapieresistente Depression. *J Neurol Neurochir Psychiatr* (2006) 7(1):43-46.

Holsboer-Trachsler, E., Hemmeter, U., Stohler, R. The dexamethasone-hCRH stimulation test and cognitive performance during antidepressive treatment with trimipramine. *European Neuropsychopharmacology* (1991) 1(3):338-340.

Hübl, W. Glucocorticoid-Hormone. www.med4you.at/laborbefunde, 2005.

Hudson, J. I., Hudson, M. S., Rothschild, A. J., et al. Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. *Arch Gen Psychiatry* (1984) 41(11):1086-9.

Hundt, W., Zimmermann, U., Pottig, M., et al. The combined dexamethasone-suppression/CRH-stimulation test in alcoholics during and after acute withdrawal. *Alcohol Clin Exp Res* (2001) 25(5):687-91.

Hunt, G. E., O'Sullivan, B. T., Johnson, G. F., et al. Effect of high plasma dexamethasone levels on DST sensitivity: dose-response study in depressed patients and controls. *Psychiatry Res* (1991) 36(2):209-22.

Imura, H., Nakai, Y., and Yoshimi, T. Effect of 5-hydroxytryptophan (5-HTP) on growth hormone and ACTH release in man. *J Clin Endocrinol Metab* (1973) 36(1):204-6.

Inder, W. J., Prickett, T. C., Mulder, R. T., et al. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. *Psychopharmacology (Berl)* (2001) 156(1):73-8.

Jahn, H. Die NPR-A Knock-out Maus: Implikationen für den Zusammenhang von HHN-Achsenaktivität und Verhaltensänderungen. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2004) 75(Suppl 2):282.

Jahn, H., Rädler, T., and Wiedemann, K. Neuroendokrinologie. In A. Rohde and A. Marneros, eds., *Geschlechtsspezifische Psychiatrie und Psychotherapie*. Kohlhammer Verlag, 2007.

Kalin, N. H., Weiler, S. J., and Shelton, S. E. Plasma ACTH and cortisol concentrations before and after dexamethasone. *Psychiatry Res* (1982) 7(1):87-92.

Kasper, S., Zivkov, M., Roes, K. C., et al. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. *Eur Neuropsychopharmacol* (1997) 7(2):115-24.

Kasper, S., Gastpar, M., and Müller, W. E. Wirksamkeit von Antidepressiva: Differenzierte Bewertung statt Pauschalkritik ist gefragt. *PPT, Diskussionsforum* (2005) 12(5):193-4.

Kasper, S., Möller, H.-J., Müller-Spahn, F. *Depression. Diagnose und Pharmakotherapie*. Georg Thieme Verlag, 1997.

Katona, C. L., Aldridge, C. R., Roth, M., et al. The dexamethasone suppression test and prediction of outcome in patients receiving ECT. *Br J Psychiatry* (1987) 150:315-8.

Keitner, G. I., Fruzzetti, A. E., Miller, I. W., et al. The effect of anticonvulsants on the dexamethasone suppression test. *Can J Psychiatry* (1989) 34(5):441-3.

Kern, W., Fehm, H. Hypothalamus-Hypophysen-Nebennierenrinden-System. In L. Thomas, ed., *Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik*. TH-Books Verlagsgesellschaft, 2000.

Kessler, R. C., Berglund, P., Demler, O., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *Jama* (2003) 289(23):3095-105.

Kin, N. M., Nair, N. P., Amin, M., et al. The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline. *Biol Psychiatry* (1997) 42(10):925-31.

King, D. J., Devaney, N. M., and Cooper, S. J. Rapid normalization of the dexamethasone suppression test with mianserin. *Int Clin Psychopharmacol* (1987) 2(2):111-6.

Kirschbaum, C., Wust, S., and Strasburger, C. J. 'Normal' cigarette smoking increases free cortisol in habitual smokers. *Life Sci* (1992) 50(6):435-42.

Kirschbaum, C., Prussner, J. C., Stone, A. A., et al. Persistent high cortisol responses to repeated psychological stress in a subpopulation of healthy men. *Psychosom Med* (1995) 57(5):468-74.

Kirschbaum, C., Schommer, N., Federenko, I., et al. Short-term estradiol treatment enhances pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men. *J Clin Endocrinol Metab* (1996) 81(10):3639-43.

Kirschbaum, C., Kudielka, B. M., Gaab, J., et al. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. *Psychosom Med* (1999) 61(2):154-62.

Kirstein, L. Neuroendocrine dysfunction and response to tricyclic antidepressants. *J Clin Psychiatry* (1984) 45(9):385-6.

Kline, M. D., and Beeber, A. R. Weight loss and the dexamethasone suppression test. *Arch Gen Psychiatry* (1983) 40(9):1034-5.

Kroll, P., Palmer, C., and Greden, J. F. The dexamethasone suppression test in patients with alcoholism. *Biol Psychiatry* (1983) 18(4):441-50.

Kuhs, H., and Mester, H. [Dexamethasone suppression test in anorexia nervosa]. *Eur Arch Psychiatry Neurol Sci* (1985) 234(5):335-40.

Kunugi, H., Ida, I., Owashi, T., et al. Assessment of the Dexamethasone/CRH Test as a State-Dependent Marker for Hypothalamic-Pituitary-Adrenal (HPA) Axis Abnormalities in Major Depressive Episode: A Multicenter Study. *Neuropsychopharmacology* (2005).

Kunzel, H. E., Binder, E. B., Nickel, T., et al. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. *Neuropsychopharmacology* (2003) 28(12):2169-78.

Laakmann, G., Schule, C., Baghai, T., et al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. *Psychoneuroendocrinology* (1999) 24(7):769-84.

Laakmann, G., Hennig, J., Baghai, T., et al. Influence of mirtazapine on salivary cortisol in depressed patients. *Neuropsychobiology* (2003) 47(1):31-6.

Laakmann, G., Hennig, J., Baghai, T., et al. Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients. *Ann N Y Acad Sci* (2004) 1032:279-82.

Lahmeyer, H. W., Val, E., Gaviria, F. M., et al. EEG sleep, lithium transport, dexamethasone suppression, and monoamine oxidase activity in borderline personality disorder. *Psychiatry Res* (1988) 25(1):19-30.

Lammers, C. H., Garcia-Borreguero, D., Schmider, J., et al. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. *Biol Psychiatry* (1995) 38(12):803-7.

Lange, W., Wulff, H. Berea, C. Dexamethasone suppression test in borderline personality disorder - effects of posttraumatic stress disorder. *Psychoneuroendocrinology* (2005) 30(9):919-23.

Lederbogen, F., Gilles, M., Maras, A., et al. Increased platelet aggregability in major depression? *Psychiatry Res* (2001) 102(3):255-61.

Lederbogen, F., Deuschle, M. [Dysfunction of the hypothalamus-pituitary-adrenal system--background variable of relevant cardiovascular risk factors?--description of a cooperative project]. *Gesundheitswesen* (2005) 67 Suppl 1:S94-7.

Lenox, R. H., Peyser, J. M., Rothschild, B., et al. Failure to normalize the dexamethasone suppression test: association with length of illness. *Biol Psychiatry* (1985) 20(3):333-7.

Lesch, K. P., and Rupprecht, R. Psychoneuroendocrine research in depression. II. Hormonal responses to releasing hormones as a probe for hypothalamic-pituitary-endorgan dysfunction. *J Neural Transm* (1989) 75(3):179-94.

Lester, D. The dexamethasone suppression test as an indicator of suicide: a meta-analysis. *Pharmacopsychiatry* (1992) 25(6):265-70.

Lieb, K., Berger, M. Neurobiologische Prädiktoren für das Ansprechen auf Psychotherapie und Pharmakotherapie bei depressiven Störungen. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2003) 74(Suppl 2):212.

Lieb, K., Rexhausen, J. E., Kahl, K. G. Increased diurnal salivary cortisol in woman with borderline personality disorder. *J Psychiatr Res* (2004) 38(6):559-65.

Linkowski, P., Mendlewicz, J., Leclercq, R., et al. The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness. *J Clin Endocrinol Metab* (1985) 61(3):429-38.

Lipman, R. S., Uffner, W., Schwalb, N., et al. Dexamethasone Suppression Test as a Predictor of Response to Electroconvulsive Therapy. II. Six-Month Follow-Up. *Convuls Ther* (1986a) 2(3):161-167.

Lipman, R. S., Backup, C., Bobrin, Y., et al. Dexamethasone Suppression Test as a Predictor of Response to Electroconvulsive Therapy. I. Inpatient Treatment. *Convuls Ther* (1986b) 2(3):151-160.

Lohr, M. *Pathophysiologie, Pathobiochemie*. Georg Thieme Verlag, 2002.

Lowy, M. T., and Meltzer, H. Y. Dexamethasone bioavailability: implications for DST research. *Biol Psychiatry* (1987) 22(3):373-85.

Lucka, C., Adli, M., Baethge, C. Lithium augmentation and than? A long-term follow up investigation of unipolar depressed patients after lithium augmentation with special regard to clinical and neuroendocrine parameters. *Der Nervenarzt, DGPPN-Kongress, Posterpräsentation* (2003) 74(Suppl 2):216.

Lupien, S. J., de Leon, M., de Santi, S., et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. *Nat Neurosci* (1998) 1(1):69-73.

Maes, M., Calabrese, J., and Meltzer, H. Y. The relevance of the in- versus outpatient status for studies on HPA-axis in depression: spontaneous hypercortisolism is a

feature of major depressed inpatients and not of major depression per se. *Prog Neuropsychopharmacol Biol Psychiatry* (1994) 18(3):503-17.

Maj, M., Pirozzi, R., and Di Caprio, E. L. Major depression with mood-congruent psychotic features: a distinct diagnostic entity or a more severe subtype of depression? *Acta Psychiatr Scand* (1990) 82(6):439-44.

Majumdar, S. K., Shaw, G. K., and Bridges, P. K. The dexamethasone suppression test in chronic alcoholics with and without depression and its relationship to their hepatic status. *Drug Alcohol Depend* (1988) 21(3):231-5.

Mason, J. W., Sachar, E. J., Fishman, J. R., et al. Corticosteroid Responses to Hospital Admission. *Arch Gen Psychiatry* (1965) 13:1-8.

McAllister, T. W., and Price, T. R. Clinical and DST response to bilateral sinusoidal but not to unilateral brief-pulse ECT. *J Clin Psychiatry* (1986) 47(11):557-9.

McLeod, W. R., Carroll, B., Davies, B. Hypothalamic dysfunction and antidepressant drugs. *Br Med J* (1970) 2:480-1.

Meador-Woodruff, J. H., Greden, J. F., Grunhaus, L., et al. Severity of depression and hypothalamic-pituitary-adrenal axis dysregulation: identification of contributing factors. *Acta Psychiatr Scand* (1990) 81(4):364-71.

Mendlewicz, J., Charon, F., and Linkowski, P. Life events and the dexamethasone suppression test in affective illness. *J Affect Disord* (1986) 10(3):203-6.

Mendlewicz, J., Lecrubier, Y. Antidepressant selection: proceedings from a TCA/SSRI Consensus Conference. *Acta Psychiatr Scand* (2000) 101(Suppl. 403):5-8.

Miller, K. B., and Nelson, J. C. Does the dexamethasone suppression test relate to subtypes, factors, symptoms, or severity? *Arch Gen Psychiatry* (1987) 44(9):769-74.

Modell, S., Lauer, C. J., Schreiber, W., et al. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. *Neuropsychopharmacology* (1998) 18(4):253-62.

Moller, H. J., Fuger, J., and Kasper, S. Efficacy of new generation antidepressants: meta-analysis of imipramine-controlled studies. *Pharmacopsychiatry* (1994) 27(6):215-23.

Müller, O. A. Nebennierenerkrankungen. In M. Classen, Diehl, V., Kochsiek, K., ed., *Innere Medizin*. Urban & Schwarzenberg, 1993.

Nelson, J. C., Mazure, C. M., and Jatlow, P. I. Value of the DST for predicting response of patients with major depression to hospitalization and desipramine. *Am J Psychiatry* (1990) 147(11):1488-92.

Nelson, J. C., and Davis, J. M. DST studies in psychotic depression: a meta-analysis. *Am J Psychiatry* (1997) 154(11):1497-503.

Nelson, J. C. Managing treatment-resistant major depression. *J Clin Psychiatry* (2003) 64 Suppl 1:5-12.

Nelson, W. H., Orr, W. W., Jr., Stevenson, J. M., et al. Hypothalamic-pituitary-adrenal axis activity and tricyclic response in major depression. *Arch Gen Psychiatry* (1982) 39(9):1033-6.

Nelson, W. H., Sullivan, P., Khan, A. The effect of age on dexamethasone suppression test results in alcoholic patients. *Am J Psychiatry* (1986) 143(2):237-9.

Nemeroff, C. B., Widerlov, E., Bissette, G., et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. *Science* (1984) 226(4680):1342-4.

Nemeroff, C. B., and Evans, D. L. Correlation between the dexamethasone suppression test in depressed patients and clinical response. *Am J Psychiatry* (1984) 141(2):247-9.

Nemeroff, C. B., Owens, M. J., Bissette, G., et al. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. *Arch Gen Psychiatry* (1988) 45(6):577-9.

Nemeroff, C. B., and Owens, M. J. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. *CNS Spectr* (2004) 9(6 Suppl 4):23-31.

Neumann, F., Schenck, B., Schleussner, H. Endokrinpharmakologie. In W. Forth, Henschler, D., ed., *Pharmakologie und Toxikologie*. Spektrum Akademischer Verlag, 1998.

Nickel, T., Sonntag, A., Schill, J., et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. *J Clin Psychopharmacol* (2003) 23(2):155-68.

Nierenberg, A. A., and Feinstein, A. R. How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test. *Jama* (1988) 259(11):1699-702.

Nierenberg, A. A., and DeCecco, L. M. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. *J Clin Psychiatry* (2001) 62 Suppl 16:5-9.

O'Brien, J. T., Ames, D., Schweitzer, I., et al. Clinical and magnetic resonance imaging correlates of hypothalamic-pituitary-adrenal axis function in depression and Alzheimer's disease. *Br J Psychiatry* (1996) 168(6):679-87.

Oeljeschläger, B., Müller-Oerlinghausen, B. Wege zur Optimierung der individuellen antidepressiven Therapie. *Deutsches Ärzteblatt* (2004) 101(19):1337-40.

O'Reardon, J. P., Amsterdam, J.D. Treatment-Resistant Depression: Progress and Limitations. *Psychiatric Annals* (1998) 28(11):633-640.

Osuch, E. A., Cora-Locatelli, G., Frye, M. A., et al. Post-dexamethasone cortisol correlates with severity of depression before and during carbamazepine treatment in women but not men. *Acta Psychiatr Scand* (2001) 104(5):397-401.

O'Sullivan, B. T., Hunt, G. E., Johnson, G. F., et al. The plasma dexamethasone window: evidence supporting its usefulness to validate dexamethasone suppression test results. *Biol Psychiatry* (1989) 25(6):739-54.

O'Sullivan, B. T., Cutler, D. J., Hunt, G. E., et al. Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. *Biol Psychiatry* (1997) 41(5):574-84.

Otte, C., Hart, S., Neylan, T. C., et al. A meta-analysis of cortisol response to challenge in human aging: importance of gender. *Psychoneuroendocrinology* (2005) 30(1):80-91.

Pagnin, D., de Queiroz, V., Pini, S., et al. Efficacy of ECT in depression: a meta-analytic review. *J Ect* (2004) 20(1):13-20.

Palmer, R. L., Mani, C., Abdel-Kariem, M. A., et al. Dexamethasone Suppression Tests in the Context of a Double-Blind Trial of Electroconvulsive Therapy and Simulated ECT. *Convuls Ther* (1990) 6(1):13-18.

Papakostas, Y., Fink, M., Lee, J., et al. Neuroendocrine measures in psychiatric patients: course and outcome with ECT. *Psychiatry Res* (1981) 4(1):55-64.

Pariante, C. M., and Miller, A. H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. *Biol Psychiatry* (2001) 49(5):391-404.

Pariante, C. M. Depression, stress and the adrenal axis. *J Neuroendocrinol* (2003) 15(8):811-2.

Parker, K. J., Schatzberg, A. F., and Lyons, D. M. Neuroendocrine aspects of hypercortisolism in major depression. *Horm Behav* (2003) 43(1):60-6.

Perry, P. J. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. *J Affect Disord* (1996) 39(1):1-6.

Peselow, E. D., and Fieve, R. R. Dexamethasone suppression test and response to antidepressants in depressed outpatients. *N Engl J Med* (1982) 307(19):1216-7.

Peselow, E. D., Lautin, A., Wolkin, A., et al. The dexamethasone suppression test and response to placebo. *J Clin Psychopharmacol* (1986) 6(5):286-91.

Peselow, E. D., Baxter, N., Fieve, R. R., et al. The dexamethasone suppression test as a monitor of clinical recovery. *Am J Psychiatry* (1987) 144(1):30-5.

Peselow, E. D., Stanley, M., Filippi, A. M., et al. The predictive value of the dexamethasone suppression test. A placebo-controlled study. *Br J Psychiatry* (1989) 155:667-72.

Pfennig, A., Kunzel, H. E., Kern, N., et al. Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. *Biol Psychiatry* (2005) 57(4):336-42.

Pfohl, B., Sherman, B., Schlechte, J., et al. Differences in plasma ACTH and cortisol between depressed patients and normal controls. *Biol Psychiatry* (1985) 20(10):1055-72.

Philipp, M., Maier, W., and Holsboer, F. Psychopathological correlates of plasma cortisol after dexamethasone suppression: a polydiagnostic approach. *Psychoneuroendocrinology* (1986) 11(4):499-507.

Pickworth, W. B., and Fant, R. V. Endocrine effects of nicotine administration, tobacco and other drug withdrawal in humans. *Psychoneuroendocrinology* (1998) 23(2):131-41.

Poland, R. E., Rubin, R. T., Lesser, I. M., et al. Neuroendocrine aspects of primary endogenous depression. II. Serum dexamethasone concentrations and hypothalamic-pituitary-adrenal cortical activity as determinants of the dexamethasone suppression test response. *Arch Gen Psychiatry* (1987) 44(9):790-5.

Poland, R. E., Rubin, R. T., and Lesser, I. M. Serum dexamethasone concentrations in endogenous depressives before, during, and after treatment: preliminary observations. *Biol Psychiatry* (1988) 23(7):705-10.

Posener, J. A., DeBattista, C., Williams, G. H., et al. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. *Arch Gen Psychiatry* (2000) 57(8):755-60.

Privitera, M. R., Greden, J. F., Gardner, R. W., et al. Interference by carbamazepine with the dexamethasone suppression test. *Biol Psychiatry* (1982) 17(5):611-20.

Pschyrembel, W. *Klinisches Wörterbuch*. Walter de Gruyter, 1994.

Regen, F., Merkl, A., Heuser, I., et al. [Diabetes and depression]. *Dtsch Med Wochenschr* (2005) 130(17):1097-102.

Reul, J. M., Stec, I., Soder, M., et al. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. *Endocrinology* (1993) 133(1):312-20.

Ribeiro, S. C., Tandon, R., Grunhaus, L., et al. The DST as a predictor of outcome in depression: a meta-analysis. *Am J Psychiatry* (1993) 150(11):1618-29.

Ritchie, J. C., Belkin, B. M., Krishnan, K. R., et al. Plasma dexamethasone concentrations and the dexamethasone suppression test. *Biol Psychiatry* (1990) 27(2):159-73.

Roose, S. P., Glassman, A. H., Attia, E., et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. *Am J Psychiatry* (1994) 151(12):1735-9.

Roy, A., Gold, P., Pickar, D., et al. Pre- and post-dexamethasone plasma ACTH levels in depressed patients and normal controls. *J Affect Disord* (1986) 10(2):95-9.

Rubin, R. T., Poland, R. E., Lesser, I. M., et al. Neuroendocrine aspects of primary endogenous depression. III. Cortisol secretion in relation to diagnosis and symptom patterns. *Psychol Med* (1987) 17(3):609-19.

Rubin, R. T. Pharmacoendocrinology of major depression. *Eur Arch Psychiatry Neurol Sci* (1989) 238(5-6):259-67.

Rubin, R. T., Phillips, J. J., Sadow, T. F., et al. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. *Arch Gen Psychiatry* (1995) 52(3):213-8.

Rupprecht, R., and Lesch, K. P. Psychoneuroendocrine research in depression. I. Hormone levels of different neuroendocrine axes and the dexamethasone suppression test. *J Neural Transm* (1989) 75(3):167-78.

Rupprecht, R. Neuentwicklungen in der Pharmakotherapie der Depression: ein Überblick. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2003) 74(Suppl 2):225.

Rush, A. J., Weissenburger, J., Vasavada, N., et al. Dexamethasone suppression test status does not predict differential response to nortriptyline versus amitriptyline. *J Clin Psychopharmacol* (1988) 8(6):421-5.

Rush, A. J., Giles, D. E., Schlesser, M. A., et al. The dexamethasone suppression test in patients with mood disorders. *J Clin Psychiatry* (1996) 57(10):470-84.

Russo-Neustadt, A. A., and Chen, M. J. Brain-derived neurotrophic factor and antidepressant activity. *Curr Pharm Des* (2005) 11(12):1495-510.

Rybakowski, J. K., and Twardowska, K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. *J Psychiatr Res* (1999) 33(5):363-70.

Sachar, E. J., Hellman, L., Fukushima, D. K., et al. Cortisol production in depressive illness. A clinical and biochemical clarification. *Arch Gen Psychiatry* (1970) 23(4):289-98.

Sachar, E. J., Roffwarg, H. P., Gruen, P. H., et al. Neuroendocrine studies of depressive illness. *Pharmakopsychiatr Neuropsychopharmakol* (1976) 9(1):11-7.

Sachar, E. J. Neuroendocrine dysfunction in depressive illness. *Annu Rev Med* (1976) 27:389-96.

Sapolsky, R. M. Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion. *Stress* (1996) 1(1):1-19.

Sarandol, A., Taneli, B., and Sivrioglu, Y. [Hypothalamic-pituitary-adrenal and hypothalamic-pituitary-thyroid axis findings in depressive disorder]. *Turk Psikiyatri Derg* (2003) 14(2):116-24.

Schildkraut, J. J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. *Am J Psychiatry* (1965) 122(5):509-22.

Schlesser, M. A., Winokur, G., and Sherman, B. M. Genetic subtypes of unipolar primary depressive illness distinguished by hypothalamic-pituitary-adrenal axis activity. *Lancet* (1979) 1(8119):739-41.

Schlesser, M. A., Winokur, G., and Sherman, B. M. Hypothalamic-pituitary-adrenal axis activity in depressive illness. Its relationship to classification. *Arch Gen Psychiatry* (1980) 37(7):737-43.

Schmider, J., Lammers, C. H., Gotthardt, U., et al. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. *Biol Psychiatry* (1995) 38(12):797-802.

Schmidt-Matthiesen, H. *Gynäkologie und Geburtshilfe*. Schattauer Verlag, 1992.

Schommer, N. C., Hellhammer, D. H., and Kirschbaum, C. Dissociation between reactivity of the hypothalamus-pituitary-adrenal axis and the sympathetic-adrenal-medullary system to repeated psychosocial stress. *Psychosom Med* (2003) 65(3):450-60.

Schreiber, W., Lauer, C. J., Krumrey, K., et al. Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. *Neuropsychopharmacology* (1996) 15(1):7-15.

Schule, C., Baghai, T., Zwanzger, P., et al. Attenuation of HPA axis hyperactivity and simultaneous clinical deterioration in a depressed patient treated with mirtazapine. *World J Biol Psychiatry* (2001a) 2(2):103-5.

Schule, C., Baghai, T., Zwanzger, P., et al. Sleep deprivation and hypothalamic-pituitary-adrenal (HPA) axis activity in depressed patients. *J Psychiatr Res* (2001b) 35(4):239-47.

Schule, C., Baghai, T., Goy, J., et al. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. *Psychopharmacology (Berl)* (2002) 163(1):95-101.

Schule, C., Baghai, T., Rackwitz, C., et al. Influence of mirtazapine on urinary free cortisol excretion in depressed patients. *Psychiatry Res* (2003a) 120(3):257-64.

Schule, C., Baghai, T., Zwanzger, P., et al. Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. *Psychopharmacology (Berl)* (2003b) 166(3):271-5.

Schule, C., Baghai, T., Sauer, N., et al. Endocrinological effects of high-dose Hypericum perforatum extract WS 5570 in healthy subjects. *Neuropsychobiology* (2004a) 49(2):58-63.

Schule, C., Baghai, T., and Laakmann, G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. *Neuroendocrinology* (2004b) 79(1):54-62.

Schule, C., Baghai, T., Schmidbauer, S., et al. Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. *Psychoneuroendocrinology* (2004c) 29(2):185-200.

Schüle, C. Einfluss von Mirtazapin auf das Hypothalamus-Hypophysen-Nebennierenrinden-System (HHN) bei depressiven Patienten. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2003) 74(Suppl 2):205.

Schüle, C. Aktivität des HHN-Systems und antidepressive Wirksamkeit bei akut depressiven Patienten. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2006) 77(Suppl 3):356.

Schürmeyer, T. H. Dynamische Systemerkrankungen: Stress. In R. Hesch, ed., *Innere Medizin der Gegenwart: Endokrinologie, Bd. 5, Teil B*. Urban & Schwarzenberg, 1989.

Schweiger, U., Deuschle, M., Korner, A., et al. Low lumbar bone mineral density in patients with major depression. *Am J Psychiatry* (1994) 151(11):1691-3.

Schweitzer, I., Maguire, K. P., Gee, A. H., et al. Prediction of outcome in depressed patients by weekly monitoring with the dexamethasone suppression test. *Br J Psychiatry* (1987) 151:780-4.

Shapiro, M. F., and Lehman, A. F. The diagnosis of depression in different clinical settings. An analysis of the literature on the dexamethasone suppression test. *J Nerv Ment Dis* (1983) 171(12):714-20.

Silbernagel, S. Hormone, Reproduktion. In S. Silbernagel, Despopoulos, A., ed., *Taschenatlas der Physiologie*. Thieme Verlag, 2003.

Simon, J. S., Evans, D. L., and Nemeroff, C. B. The dexamethasone suppression test and antidepressant response in major depression. *J Psychiatr Res* (1987) 21(3):313-7.

Skare, S., Pew, B., and Dysken, M. The dexamethasone suppression test in dementia: a review of the literature. *J Geriatr Psychiatry Neurol* (1990) 3(3):124-38.

Smith, D., Dempster, C., Glanville, J., et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. *Br J Psychiatry* (2002) 180:396-404.

Sonntag, A., Rothe, B., Guldner, J., et al. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. *Depression* (1996) 4(1):1-13.

Spar, J. E., and Gerner, R. Does the dexamethasone suppression test distinguish dementia from depression? *Am J Psychiatry* (1982) 139(2):238-40.

Spar, J. E., and La Rue, A. Major depression in the elderly: DSM-III criteria and the dexamethasone suppression test as predictors of treatment response. *Am J Psychiatry* (1983) 140(7):844-7.

Steardo, L., Barone, P., Monteleone, P., et al. Is the dexamethasone suppression test predictive of response to specific antidepressant treatment in major depression? *Acta Psychiatr Scand* (1987) 76(2):129-33.

Steckler, T., Holsboer, F., and Reul, J. M. Glucocorticoids and depression. *Baillieres Best Pract Res Clin Endocrinol Metab* (1999) 13(4):597-614.

Steiger, A., Benkert, O., Wohrmann, S., et al. Effects of trimipramine on sleep EEG, penile tumescence and nocturnal hormonal secretion. A long-term study in 3 normal controls. *Neuropsychobiology* (1989) 21(2):71-5.

Stevens, A. Wie schnell wirken Antidepressiva verglichen mit Placebo - eine Meta-Analyse. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2004) 75(Suppl 2):129.

Stokes, P. E., Pick, G. R., Stoll, P. M., et al. Pituitary-Adrenal Function In Depressed Patients: Resistance To Dexamethasone Suppression. *J Psychiatr Res* (1975) 12:271-281.

Stokes, P. E., Sikes, C., Lasley, B., et al. HPA hyperactivity with increased plasma cortisol affects dexamethasone metabolism and DST outcome. *J Psychiatr Res* (2002) 36(6):417-21.

Stout, S. C., Owens, M. J., and Nemeroff, C. B. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. *J Pharmacol Exp Ther* (2002) 300(3):1085-92.

Strohle, A. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety]. *Nervenarzt* (2003) 74(3):279-91; quiz 292.

Swartz, C. M., Breen, K., and Wahby, V. S. Pharmacologic provocation and dexamethasone suppression test sensitivity. *Neuropsychobiology* (1989) 22(1):11-3.

Szegedi, A. Wann beginnen Antidepressiva zu wirken? *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2003) 74(Suppl 2):211.

Targum, S. D., Rosen, L., and Capodanno, A. E. The dexamethasone suppression test in suicidal patients with unipolar depression. *Am J Psychiatry* (1983) 140(7):877-9.

Targum, S. D. Reported weight loss and the dexamethasone suppression test. *Psychiatry Res* (1983) 9(2):173-4.

Targum, S. D. Serial dexamethasone tests for predicting relapse in depressive disorder. *South Med J* (1984a) 77(11):1402-5.

Targum, S. D. Persistent neuroendocrine dysregulation in major depressive disorder: a marker for early relapse. *Biol Psychiatry* (1984b) 19(3):305-18.

Thase, M. E., and Rush, A. J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. *J Clin Psychiatry* (1997) 58 Suppl 13:23-9.

Thase, M. E., Entsuah, A. R., and Rudolph, R. L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. *Br J Psychiatry* (2001) 178:234-41.

Thase, M. E., Lu, Y., Joliat, M, Detke, M.J. Remission in Placebo-Controlled Trials of Duloxetine with an SSRI Comparator. *Biol Psychiatry, Abstract* (2004) 55:37S.

Timmerman, L., de Beurs, P., Tan, B. K., et al. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients. *Int Clin Psychopharmacol* (1987) 2(3):239-53.

Torpy, D. J., Grice, J. E., Hockings, G. I., et al. Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans. *J Clin Endocrinol Metab* (1994) 79(1):140-4.

Van Cauter, E., Leproult, R., and Kupfer, D. J. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. *J Clin Endocrinol Metab* (1996) 81(7):2468-73.

Van Loon, G. R., Scapagnini, U., Moberg, G. P., et al. Evidence for central adrenergic neural inhibition of ACTH secretion in the rat. *Endocrinology* (1971) 89(6):1464-9.

Van Wijnendaele, R., Hubain, P., Dramaix, M., et al. [Influence of depressive history on biological parameters in major depression]. *Encephale* (2002) 28(1):51-8.

Vedder, H., Enning, F., Fischer, S., Krieg, J.-C. Endokrinokogische Aspekte der antidepressiven Therapie mit Hypericum Perforatum. *Der Nervenarzt, DGPPN-Kongress, Abstractband* (2004) 75(Suppl 2):321.

Vetter, W., Bachmann, L.M. Nebennierenrinde. In W. Siegenthaler, ed., *Klinische Pathophysiologie*. Georg Thieme Verlag, 2001.

von Bardeleben, U., Wiedemann, K., Stalla, G. K., et al. Exaggerated corticotrophic cell response to human corticotropin-releasing hormone in two patients during long-term carbamazepine treatment. *Biol Psychiatry* (1988) 24(3):331-5.

von Zerssen, D., Berger, M., and Doerr, P. Neuroendocrinological studies on depression with special reference to research at the Max-Planck-Institute of Psychiatry. *Pharmacopsychiatry* (1987) 20(1):8-22.

Vrkljan, M., Thaller, V., Lovricevic, I., et al. Depressive disorder as possible risk factor of osteoporosis. *Coll Antropol* (2001) 25(2):485-92.

Vythilingam, M., Chen, J., Bremner, J. D., et al. Psychotic depression and mortality. *Am J Psychiatry* (2003) 160(3):574-6.

Walsh, B. T., Seidman, S. N., Sysko, R., et al. Placebo response in studies of major depression: variable, substantial, and growing. *Jama* (2002) 287(14):1840-7.

Watson, S., Gallagher, P., Del-Estal, D., et al. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. *Psychol Med* (2002) 32(6):1021-8.

Watson, S., Gallagher, P., Ritchie, J. C., et al. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. *Br J Psychiatry* (2004) 184:496-502.

Weber, B., Schweiger, U., Deuschle, M., et al. Major depression and impaired glucose tolerance. *Exp Clin Endocrinol Diabetes* (2000) 108(3):187-90.

Weber-Hamann, B., Hentschel, F., Kniest, A., et al. Hypercortisolemic depression is associated with increased intra-abdominal fat. *Psychosom Med* (2002) 64(2):274-7.

Weber-Hamann, B., Kopf, D., Lederbogen, F., et al. Activity of the hypothalamus-pituitary-adrenal system and oral glucose tolerance in depressed patients. *Neuroendocrinology* (2005a) 81(3):200-4.

Weber-Hamann, B., Werner, M., Hentschel, F., et al. Metabolic changes in elderly patients with major depression: Evidence for increased accumulation of visceral fat at follow-up. *Psychoneuroendocrinology* (2005b).

Weiner, R. I., and Ganong, W. F. Role of brain monoamines and histamine in regulation of anterior pituitary secretion. *Physiol Rev* (1978) 58(4):905-76.

Weppner, G. J. The effect of benzodiazepine withdrawal on the dexamethasone suppression test. *Acta Psychiatr Scand* (1988) 77(2):232-4.

Wheatley, D. P., van Moffaert, M., Timmerman, L., et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. *J Clin Psychiatry* (1998) 59(6):306-12.

Whiteford, H. A., Peabody, C. A., Csernansky, J. G., et al. The severity of depression and nonsuppression on the DST. *Am J Psychiatry* (1986) 143(12):1634-5.

Wichniak, A., Brunner, H., Ising, M., et al. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression. *Psychoneuroendocrinology* (2004) 29(9):1101-8.

Wiedemann, K., and Holsboer, F. Plasma dexamethasone kinetics during the DST after oral and intravenous administration of the test drug. *Biol Psychiatry* (1987) 22(11):1340-8.

Wiedemann, K., and Holsboer, F. The effect of dexamethasone dosage upon plasma cortisol and dexamethasone during the DST. *J Affect Disord* (1990) 19(2):133-7.

Wik, G., Wiesel, F. A., Eneroth, P., et al. Dexamethasone suppression test in schizophrenic patients before and during neuroleptic treatment. *Acta Psychiatr Scand* (1986) 74(2):161-7.

Wirtz, M., Nachtigall, C. *Deskriptive Statistik*. Juventa Verlag, 1998.

Wolf, O. T., Convit, A., de Leon, M. J., et al. Basal hypothalamo-pituitary-adrenal axis activity and corticotropin feedback in young and older men: relationships to magnetic resonance imaging-derived hippocampus and cingulate gyrus volumes. *Neuroendocrinology* (2002) 75(4):241-9.

Wolkowitz, O. M., Reus, V. I., Weingartner, H., et al. Cognitive effects of corticosteroids. *Am J Psychiatry* (1990) 147(10):1297-303.

Wust, S., Wolf, J., Hellhammer, D. H., et al. The cortisol awakening response - normal values and confounds. *Noise Health* (2000) 2(7):79-88.

Yehuda, R., Southwick, S. M., Krystal, J. H., et al. Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. *Am J Psychiatry* (1993) 150(1):83-6.

Yehuda, R. Current status of cortisol findings in post-traumatic stress disorder. *Psychiatr Clin North Am* (2002) 25(2):341-68, vii.

Yerevanian, B. I., Olafsdottir, H., Milanese, E., et al. Normalization of the dexamethasone suppression test at discharge from hospital. Its prognostic value. *J Affect Disord* (1983) 5(3):191-7.

Yerevanian, B. I., Privitera, M. R., Milanese, E., et al. The dexamethasone suppression test during recurrent major depressive episodes. *Biol Psychiatry* (1984) 19(3):407-12.

Yerevanian, B. I., Feusner, J. D., Koek, R. J., et al. The dexamethasone suppression test as a predictor of suicidal behavior in unipolar depression. *J Affect Disord* (2004) 83(2-3):103-8.

Young, E. A., Altemus, M., Lopez, J. F., et al. HPA axis activation in major depression and response to fluoxetine: a pilot study. *Psychoneuroendocrinology* (2004) 29(9):1198-204.

Yuuki, N., Ida, I., Oshima, A., et al. HPA axis normalization, estimated by DEX/CRH test, but less alteration on cerebral glucose metabolism in depressed patients receiving ECT after medication treatment failures. *Acta Psychiatr Scand* (2005) 112(4):257-65.

Zimmerman, U., Spring, K., Koller, G., et al. Hypothalamic-pituitary-adrenal system regulation in recently detoxified alcoholics is not altered by one week of treatment with acamprosate. *Pharmacopsychiatry* (2004) 37(3):98-102.

Zobel, A., Wellmer, J., Schulze-Rauschenbach, S., et al. Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. *Eur Arch Psychiatry Clin Neurosci* (2004a) 254(5):303-11.

Zobel, A. W., Yassouridis, A., Frieboes, R. M., et al. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. *Am J Psychiatry* (1999) 156(6):949-51.

Zobel, A. W., Nickel, T., Sonntag, A., et al. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. *J Psychiatr Res* (2001) 35(2):83-94.

Zobel, A. W., Schulze-Rauschenbach, S., von Widdern, O. C., et al. Improvement of working but not declarative memory is correlated with HPA normalization during antidepressant treatment. *J Psychiatr Res* (2004b) 38(4):377-83.

Zoppini, G., Targher, G., Venturi, C., et al. Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. *Clin Endocrinol (Oxf)* (2004) 61(6):711-5.